Skip to main content
. 2024 Jul 11;13(14):4061. doi: 10.3390/jcm13144061

Table 1.

Characteristics of enrolled patients.

Eradicated Not-Eradicated
Number of patients 98 (61.2%) 62 (38.8) 160
  Males 60 33 93 (58.1%)
  Females 38 29 67 (41.9%)
Age (median, IQR) 64 (55–74) 57.5 (46.2–71.7) 61.5 (52–73) years
BMI (median, IQR) 24.9 (22.8–26.6) 24.1 (21.8–26.8) 24.6 (22.5–26.6) kg/m2
Fibroscan liver stiffness (median, IQR) 10.2 (6.9–17.8) 7 (5.8–9.3) 8.2 (6.3–14.9) kPa
2D SWE liver stiffness (median, IQR) 8.1 (5.4–14.7) 6.8 (5.6–8.8) 7.3 (5.6–12.3) kPa
AST (median, IQR) 20.5 (17–28.7) 35.6 (33–55.2) 27 (19–35.2) U/L
ALT (median, IQR) 19 (14–25.7) 43.5 (39.6–72.2) 24.5 (16–41.5) U/L
Total bilirubin (median, IQR) 0.6 (0.5–0.8) 0.7 (0.7–0.9) 0.7 (0.5–0.9) mg/dL
GGT (median, IQR) 24.5 (17–41.8) 42.1 (27–58) 31 (19–42.1) U/L
PLT (mean ± SD) 173.8 ± 61.4 187.1 ± 46.5 179 ± 56.3 × 109/mcL
Albumin (median, IQR) 4.1 (4–4.3) 4.1 (4–4.2) 4.1 (4–4.2) g/dL
INR (median, IQR) 1.03 (0.99–1.06) 1.04 (0.99–1.04) 1.04 (0.99–1.04)
Child–Pugh class
  A5 89 (90.8%) 56 (90.3%) 145 (90.6%)
  A6 9 (9.2%) 6 (9.7%) 15 (9.4%)
Diabetes 17 (17.3%) 7 (11.3%) 24 (15%)
Obesity 10 (10.2%) 8 (12.9%) 18 (11.2%)